GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

The biopharmaceutical company is adding 6,600 square-feet of space to the facility for its research and development and ...

For the past three years, biotechs and pharmas have renamed, rebranded and more in a bid to refresh their corporate appeal. ...

Boehringer Ingelheim will join the opening keynote at Veeva Commercial Summit Europe ... BioNTech SE, Glenmark, and GSK will ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September, and according to ...

MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), ...

Nobias Therapeutics, a clinical-stage company developing novel small-molecule therapeutics for rare diseases, has announced its intent to focus its resources on its development programs following ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug ...

“The challenge is not only a drug’s therapeutic potential, but also its commercial and financial viability.” At the same time, the industry faces external disruption. First, regulations are expected ...

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...